UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                                                       SEC File Number: 33-51218
                                                       CUSIP Number:

(Check  one):  [ ] Form  10-K [ ] Form 20-F  [ ] Form 11-K  [X] Form 10-Q
               [ ] Form 10-D  [ ] Form N-SAR [ ] Form N-CSR

         For Period Ended: August 31, 2009

         [ ]  Transition Report on Form 10-K
         [ ]  Transition Report on Form 20-F
         [ ]  Transition Report on Form 11-K
         [ ]  Transition Report on Form 10-Q
         [ ]  Transition Report on Form N-SAR
         For the Transition Period Ended: __________________

Nothing  in this  form  shall be  construed  to imply  that the  Commission  has
verified any information contained herein.

If the notification  relates to a portion of the filing checked above,  identify
the Item(s) to which the notification relates:

- --------------------------------------------------------------------------------

PART I -- REGISTRANT INFORMATION

SensiVida Medical Technologies, Inc.
- --------------------------------------------------------------------------------
Full Name of Registrant


- --------------------------------------------------------------------------------
Former Name if Applicable

77 Ridgeland Road
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)

Henrietta, NY 14623
- --------------------------------------------------------------------------------
City, State and Zip Code

PART II -- RULES 12b-25 (b) AND (c)

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate.)

         (a)      The reasons described in reasonable detail in Part III of this
                  form could not be eliminated  without  unreasonable  effort or
                  expense;

[X]      (b)      The  subject  annual  report,  semi-annual  report, transition
                  report on Form 10-K,  Form 20-F,11-K Form N-SAR or Form N-CSR,
                  or portion  thereof,  will be filed on or before the fifteenth
                  calendar day following the prescribed due date; or the subject
                  quarterly report or transition report on Form 10-Q, or portion
                  thereof  will be filed on or  before  the fifth  calendar  day
                  following the prescribed due date; and

         (c)      The  accountant's  statement or other exhibit required by Rule
                  12b-25(c) has been attached if applicable.





PART III -- NARRATIVE

State below in reasonable  detail the reasons why Forms 10-K,  20-F, 11-K, 10-Q,
N-SAR,  N-CSR, or the transition  report or portion thereof,  could not be filed
within the prescribed time period.

         The  Registrant cannot file its Quarterly  Report  on Form 10-Q for the
quarter  ended  August 31, 2009  within the  prescribed  time period  because of
delays in submitting  its  consolidated  financial  statements for review by its
auditing firm.

PART IV -- OTHER INFORMATION

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
notification.

         Jose Mir                     585                         413-9080
- --------------------------------------------------------------------------------
         (Name)                   (Area Code)                (Telephone Number)

(2) Have all other  periodic  reports  required under Section 13 or 15(d) of the
Securities  Exchange Act of 1934 or Section 30 of the Investment  Company Act of
1940  during  the  preceding  12  months  or for such  shorter  period  that the
registrant  was  required to file such  report(s)  been filed?  If answer is no,
identify report(s).
                                                                  [X] Yes [ ] No


(3) Is it anticipated that any significant  change in results of operations from
the  corresponding  period for the last  fiscal  year will be  reflected  by the
earnings statements to be included in the subject report or portion thereof?
                                                                  [ ] Yes [X] No

If so, attach an explanation of the  anticipated  change,  both  narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

                      SENSIVIDA MEDICAL TECHNOLOGIES, INC.
- --------------------------------------------------------------------------------
                  (Name of Registrant as Specified in Charter)

has  caused  this  notification  to be signed on its  behalf by the  undersigned
hereunto duly authorized.



Date: August 13, 2009                          By:      /s/Jose Mir
                                                   -----------------------------
                                                        Jose Mir
                                                        CTO

                                       2